Biomarkers as a diagnostic tool for irritable bowel syndrome

where are we?

Michael Camilleri, Houssam Halawi, Ibironke Oduyebo

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Introduction: Irritable bowel syndrome (IBS) is a common condition in clinical practice. There are currently no objective tests to rule in the disease, but rather tests to rule out other diseases. Biomarkers in IBS may provide the tools needed for diagnosis, prognosis and therapy. These include identification of differences in microbial composition, immune activation, bile acid composition, colonic transit, and alteration in sensation in subgroups of IBS patients. Areas covered: Studies included in our review were chosen based on a PubMed search for ‘biomarkers’ and ‘IBS’. We have reviewed the literature on biomarkers to appraise their accuracy, validity and whether they are actionable. We have not covered genetic associations as biomarkers in this review. Expert commentary: There is significant promise in the usefulness of biomarkers for IBS. The most promising actionable biomarkers are markers of changes in bile acid balance, such as elevated bile acid in the stool, and altered colonic transit. However, there is also potential for microbial studies and mucosal proteases as future actionable biomarkers.

Original languageEnglish (US)
Pages (from-to)303-316
Number of pages14
JournalExpert Review of Gastroenterology and Hepatology
Volume11
Issue number4
DOIs
StatePublished - Apr 3 2017

Fingerprint

Irritable Bowel Syndrome
Biomarkers
Bile Acids and Salts
PubMed
Peptide Hydrolases

Keywords

  • Bile acid
  • chromogranin
  • enterochromaffin cells
  • irritable bowel syndrome
  • lymphocytes
  • mast cells
  • microbiome
  • proteases
  • scintigraphic transit
  • visceral sensation

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Biomarkers as a diagnostic tool for irritable bowel syndrome : where are we? / Camilleri, Michael; Halawi, Houssam; Oduyebo, Ibironke.

In: Expert Review of Gastroenterology and Hepatology, Vol. 11, No. 4, 03.04.2017, p. 303-316.

Research output: Contribution to journalReview article

@article{0aea4625278541cbb38af99763244524,
title = "Biomarkers as a diagnostic tool for irritable bowel syndrome: where are we?",
abstract = "Introduction: Irritable bowel syndrome (IBS) is a common condition in clinical practice. There are currently no objective tests to rule in the disease, but rather tests to rule out other diseases. Biomarkers in IBS may provide the tools needed for diagnosis, prognosis and therapy. These include identification of differences in microbial composition, immune activation, bile acid composition, colonic transit, and alteration in sensation in subgroups of IBS patients. Areas covered: Studies included in our review were chosen based on a PubMed search for ‘biomarkers’ and ‘IBS’. We have reviewed the literature on biomarkers to appraise their accuracy, validity and whether they are actionable. We have not covered genetic associations as biomarkers in this review. Expert commentary: There is significant promise in the usefulness of biomarkers for IBS. The most promising actionable biomarkers are markers of changes in bile acid balance, such as elevated bile acid in the stool, and altered colonic transit. However, there is also potential for microbial studies and mucosal proteases as future actionable biomarkers.",
keywords = "Bile acid, chromogranin, enterochromaffin cells, irritable bowel syndrome, lymphocytes, mast cells, microbiome, proteases, scintigraphic transit, visceral sensation",
author = "Michael Camilleri and Houssam Halawi and Ibironke Oduyebo",
year = "2017",
month = "4",
day = "3",
doi = "10.1080/17474124.2017.1288096",
language = "English (US)",
volume = "11",
pages = "303--316",
journal = "Expert Review of Gastroenterology and Hepatology",
issn = "1747-4124",
publisher = "Expert Reviews Ltd.",
number = "4",

}

TY - JOUR

T1 - Biomarkers as a diagnostic tool for irritable bowel syndrome

T2 - where are we?

AU - Camilleri, Michael

AU - Halawi, Houssam

AU - Oduyebo, Ibironke

PY - 2017/4/3

Y1 - 2017/4/3

N2 - Introduction: Irritable bowel syndrome (IBS) is a common condition in clinical practice. There are currently no objective tests to rule in the disease, but rather tests to rule out other diseases. Biomarkers in IBS may provide the tools needed for diagnosis, prognosis and therapy. These include identification of differences in microbial composition, immune activation, bile acid composition, colonic transit, and alteration in sensation in subgroups of IBS patients. Areas covered: Studies included in our review were chosen based on a PubMed search for ‘biomarkers’ and ‘IBS’. We have reviewed the literature on biomarkers to appraise their accuracy, validity and whether they are actionable. We have not covered genetic associations as biomarkers in this review. Expert commentary: There is significant promise in the usefulness of biomarkers for IBS. The most promising actionable biomarkers are markers of changes in bile acid balance, such as elevated bile acid in the stool, and altered colonic transit. However, there is also potential for microbial studies and mucosal proteases as future actionable biomarkers.

AB - Introduction: Irritable bowel syndrome (IBS) is a common condition in clinical practice. There are currently no objective tests to rule in the disease, but rather tests to rule out other diseases. Biomarkers in IBS may provide the tools needed for diagnosis, prognosis and therapy. These include identification of differences in microbial composition, immune activation, bile acid composition, colonic transit, and alteration in sensation in subgroups of IBS patients. Areas covered: Studies included in our review were chosen based on a PubMed search for ‘biomarkers’ and ‘IBS’. We have reviewed the literature on biomarkers to appraise their accuracy, validity and whether they are actionable. We have not covered genetic associations as biomarkers in this review. Expert commentary: There is significant promise in the usefulness of biomarkers for IBS. The most promising actionable biomarkers are markers of changes in bile acid balance, such as elevated bile acid in the stool, and altered colonic transit. However, there is also potential for microbial studies and mucosal proteases as future actionable biomarkers.

KW - Bile acid

KW - chromogranin

KW - enterochromaffin cells

KW - irritable bowel syndrome

KW - lymphocytes

KW - mast cells

KW - microbiome

KW - proteases

KW - scintigraphic transit

KW - visceral sensation

UR - http://www.scopus.com/inward/record.url?scp=85014889829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014889829&partnerID=8YFLogxK

U2 - 10.1080/17474124.2017.1288096

DO - 10.1080/17474124.2017.1288096

M3 - Review article

VL - 11

SP - 303

EP - 316

JO - Expert Review of Gastroenterology and Hepatology

JF - Expert Review of Gastroenterology and Hepatology

SN - 1747-4124

IS - 4

ER -